Statement of Financial Activities for the Year Ended 31 October 2024
The Thalidomide
| 31.10.24 | 31.10.23 | ||||
|---|---|---|---|---|---|
| Unrestricted | Restricted | Total | Total | ||
| fund | funds | funds | funds | ||
| Notes | £ | £ | £ | £ | |
| INCOME AND ENDOWMENTS FROM | |||||
| Donations and legacies | 10,002 | 1,574 | 11,576 | 2,691 | |
| Charitable activities | |||||
| Grant income | - | 7,693 | 7,693 | - | |
| Investment income | 3 | 14,935 | 101 | 15,036 | 16,729 |
| Other income | 14,614 | - | 14,614 | 13,910 | |
| Total | 39,551 | 9,368 | 48,919 | 33,330 | |
| EXPENDITURE ON | |||||
| Charitable activities | |||||
| Staff costs | 16,335 | 582 | 16,917 | 38,288 | |
| Other charges | 54,266 | 926 | 55,192 | 99,176 | |
| Total | 70,601 | 1,508 | 72,109 | 137,464 | |
| Net gains/(losses) on investments | 44,291 | - | 44,291 | (33,956 ) | |
| NET INCOME/(EXPENDITURE) | 13,241 | 7,860 | 21,101 | (138,090 ) | |
| Transfers between funds | 10 | (1,899 ) | 1,899 | - | - |
| Net movement in funds | 11,342 | 9,759 | 21,101 | (138,090 ) | |
| RECONCILIATION OF FUNDS | |||||
| Total funds brought forward | 404,611 | 8,509 | 413,120 | 551,210 | |
| TOTAL FUNDS CARRIED FORWARD | 415,953 | 18,268 | 434,221 | 413,120 |
The notes form part of these financial
Page
The Thalidomide
Balance Sheet 31 October 2024
| Unrestricted Notes fund £ CURRENT ASSETS Debtors 7 14,749 Investments 8 386,714 Cash at bank 16,794 418,257 CREDITORS Amounts falling due within one year 9 (2,304 ) NET CURRENT ASSETS 415,953 TOTAL ASSETS LESS CURRENT LIABILITIES 415,953 NET ASSETS 415,953 FUNDS Unrestricted funds 10 Restricted funds TOTAL FUNDS |
Restricted funds £ - - 18,268 18,268 - 18,268 18,268 18,268 |
31.10.24 Total funds £ 14,749 386,714 35,062 436,525 (2,304 ) 434,221 434,221 434,221 415,953 18,268 434,221 |
31.10.23 Total funds £ 1,183 373,278 41,185 415,646 (2,526 ) 413,120 413,120 413,120 404,611 8,509 413,120 |
|---|---|---|---|
The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 October 2024.
The members have not required the company to obtain an audit of its financial statements for the year ended 31 October 2024 in accordance with Section 476 of the Companies Act 2006.
The trustees acknowledge their responsibilities for
-
(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
-
(b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.
The notes form part of these financial
continued.
Page
The Thalidomide
These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.
The financial statements were approved by the Board of Trustees and authorised for issue on .....15/03/2025....................... and were signed on its behalf by:
The notes form part of these financial
continued.
Page
The Thalidomide
Balance Sheet - continued 31 October
D Mansell D. Mansell
Mr D Mansell - Trustee
The notes form part of these financial
Page
The Thalidomide
Notes to the Financial
Statements for the Year Ended
1. GENERAL INFORMATION
The Thalidomide Society is a Charitable Incorporated Organisation (CIO). Its principal activity is to work with thalidomide and similarly impaired people, their families and supporters, providing a social network for thalidomide and similarly impaired people. Its registered office is Flat 29, Weymouth House, Hill House Mews, Bromley, BR2 0DD
Company Status
The charity is a Charitable Incorporated Organisation (CIO). It is registered on Companies House with the company number CE018092 but is not required to submit and accounts or other documents with them. The company is registered with The Charity Commission with the charity number the 231708. It is required to file an annual report with them which includes a copy of these accounts.
2. ACCOUNTING POLICIES
Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
Income
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.
Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.
Taxation
The charity is exempt from corporation tax on its charitable activities.
Fund accounting
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.
continued.
Page 10
The Thalidomide
Notes to the Financial
Statements for the Year Ended
Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.
Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.
Pension costs and other post-retirement benefits
The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.
Debtors
Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid.
continued.
Page 11
The Thalidomide
Notes to the Financial Statements - continued for the Year Ended 31
2. ACCOUNTING POLICIES
- continued Cash at bank
and in hand
Cash at bank and in hand includes cash and short-term liquid investments with a short maturity of 3 months or less from the date of acquisition or opening of the deposit or similar account.
Liabilities
Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.
Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.
3.
| INVESTMENT | 31.10.24 | 31.10.23 |
|---|---|---|
| £ | £ | |
| INCOME | ||
| Investment income | 15,036 | 16,729 |
4. TRUSTEES' REMUNERATION AND BENEFITS
There were no trustees' remuneration or other benefits for the year ended 31 October 2024 nor for the year ended 31 October 2023.
Trustees' expenses
During the year some trustees were paid expenses to cover travel costs. The amount of these payments made were £1,098 (2023 - £1,068).
5.
| STAFF | 31.10.24 | 31.10.23 |
|---|---|---|
| £ | £ | |
| COSTS | ||
| Wages and salaries | 13,602 | 32,068 |
| Other pension costs | 1,089 | 1,084 |
| 14,691 | 33,152 |
The average monthly number of employees during the year was as follows:
continued.
Page 12
The Thalidomide
31.10.24 31.10.23 1 2
Employees Notes to the Financial Statements - continued for the Year Ended 31 No employees received emoluments in excess of £60,000.
continued.
Page 13
The Thalidomide
Notes to the Financial Statements -
continued for the Year Ended 31
6. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES
| 6. | COMPARATIVES FOR THE STATE ACTIVITIES |
ENT OF | FINANC | IAL |
|---|---|---|---|---|
| Unrestricted | Restricted | Total | ||
| fund | funds | funds | ||
| £ | £ | £ | ||
| INCOME AND ENDOWMENTS FROM | ||||
| Donations and legacies | 90 | 2,601 | 2,691 | |
| Investment income | 16,681 | 48 | 16,729 | |
| Other income | 13,910 | - | 13,910 | |
| Total | 30,681 | 2,649 | 33,330 | |
| EXPENDITURE ON | ||||
| Charitable activities | ||||
| Staff costs | 29,072 | 9,216 | 38,288 | |
| Other charges | 84,461 | 14,715 | 99,176 | |
| Total | 113,533 | 23,931 | 137,464 | |
| Net gains/(losses) on investments | (33,956 ) | - | (33,956 ) | |
| NET INCOME/(EXPENDITURE) | (116,808 ) | (21,282 ) | (138,090 ) | |
| Transfers between funds | (8,000 ) | 8,000 | - | |
| Net movement in funds | (124,808 ) | (13,282 ) | (138,090 ) | |
| RECONCILIATION OF FUNDS | ||||
| Total funds brought forward | 529,419 | 21,791 | 551,210 | |
| TOTAL FUNDS CARRIED FORWARD | 404,611 | 8,509 | 413,120 | |
| 7. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR | |||
| 31.10.24 | 31.10.23 | |||
| £ | £ | |||
| PAYE & NI debtor Prepayments and accrued income |
1,183 ~~13,566~~ |
1,183 ~~-~~ |
||
| 14,749 | 1,183 |
continued.
Page 14
The Thalidomide
Notes to the Financial Statements - continued for the Year Ended 31
| 8. CURRENT ASSET INVESTMENTS Listed investments 9. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR Pension creditor Accruals and deferred income 10. MOVEMENT IN FUNDS At 1.11.23 £ Unrestricted funds General fund 404,611 Restricted funds Thalidomide Society Oral History 13,506 Srey Hang & Beyond 4,595 HLF (9,592 ) 8,509 TOTAL FUNDS 413,120 Net movement in funds, included in the above are as follows: Incoming resources £ Unrestricted funds General fund 39,551 Restricted funds Thalidomide Society Oral History 1,619 Srey Hang & Beyond 56 HLF 7,693 9,368 TOTAL FUNDS 48,919 |
Net movement in funds £ 13,241 111 56 7,693 7,860 21,101 Resources expended £ (70,601 ) (1,508 ) - - (1,508 ) (72,109 ) |
31.10.24 £ 386,714 31.10.24 £ 109 2,195 2,304 Transfers between funds £ (1,899 ) - - 1,899 1,899 - Gains and losses £ 44,291 - - - - 44,291 |
31.10.23 £ 373,278 31.10.23 £ 78 2,448 2,526 At 31.10.24 £ 415,953 13,617 4,651 - 18,268 434,221 Movement in funds £ 13,241 111 56 7,693 7,860 21,101 |
|
|---|---|---|---|---|
Page 15
continued.
The Thalidomide
Notes to the Financial Statements -
continued for the Year Ended 31
10. MOVEMENT IN FUNDS - continued
Comparatives for movement in funds
| Unrestricted funds General fund Restricted funds Thalidomide Society Oral History Support for Srey Hang HLF TOTAL FUNDS |
At 1.11.22 £ 529,419 10,898 4,556 6,337 21,791 551,210 |
Net movement in funds £ (116,808 ) 2,608 39 (23,929 ) (21,282 ) (138,090 ) |
Transfers between funds £ (8,000 ) - - 8,000 8,000 - |
At 31.10.23 £ 404,611 13,506 4,595 (9,592 ) 8,509 413,120 |
|---|---|---|---|---|
Comparative net movement in funds, included in the above are as follows:
| Unrestricted funds General fund Restricted funds Thalidomide Society Oral History Support for Srey Hang HLF TOTAL FUNDS |
Incoming resources £ 30,681 2,608 39 2 2,649 33,330 |
Resources expended £ (113,533 ) - - (23,931 ) (23,931 ) (137,464 ) |
Gains and losses £ Movement in funds £ (33,956 ) (116,808 ) - 2,608 - 39 - (23,929 ) - (21,282 ) (33,956 ) (138,090 ) |
|---|---|---|---|
11. RELATED PARTY DISCLOSURES
There were no related party transactions for the year ended 31 October 2024.
Page 16
The Thalidomide
Detailed Statement of Financial
| Detailed Statement of Financial | ||
|---|---|---|
| Activities for the Year Ended 31 | ||
| 31.10.24 | 31.10.23 | |
| £ | £ | |
| INCOME AND ENDOWMENTS | ||
| Donations and legacies | ||
| Donations | 10,003 | 1,191 |
| Lottery income | 1,573 | 1,500 |
| 11,576 | 2,691 | |
| Investment income | ||
| Investment income | 15,036 | 16,729 |
| Charitable activities | ||
| Grants | 7,693 | - |
| Other income | ||
| Delgate fees | 14,614 | 13,910 |
| Total incoming resources | 48,919 | 33,330 |
| EXPENDITURE | ||
| Support costs | ||
| Human resources | ||
| Wages | 13,602 | 32,068 |
| Pensions | 1,089 | 1,084 |
| Travel and subsistence costs | 2,226 | 5,136 |
| 16,917 | 38,288 | |
| Other | ||
| Insurance | 96 | 254 |
| Telephone and communications | 445 | 726 |
| Postage and stationery | 609 | 260 |
| Computer and IT expenses | 977 | 1,677 |
| Training seminars & workshops | 44,278 | 78,207 |
| Oral history photography costs | - | 7,946 |
| Oral history transcribing costs | - | 4,243 |
| Memberships and subscriptions | 95 | - |
| Repairs and renewals | - | 1,198 |
| Recruitment costs | - | 633 |
| Gifts | 71 | - |
| Website development | 4,560 | - |
| Investment fees | 856 | 1,137 |
| Carried forward | 51,987 | 96,281 |
This page does not form part of the statutory financial
Page 17
The Thalidomide
Detailed Statement of Financial
| Detailed Statement of Financial | ||
|---|---|---|
| Activities for the Year Ended 31 | ||
| 31.10.24 | 31.10.23 | |
| £ | £ | |
| Other | ||
| Brought forward | 51,987 | 96,281 |
| Accountancy fees | 2,130 | 2,034 |
| Legal fees | 1,075 | 861 |
| 55,192 | 99,176 | |
| Total resources expended | 72,109 | 137,464 |
| Net expenditure before gains and losses | (23,190 ) | (104,134 ) |
| Realised recognised gains and losses | ||
| Realised gains/(losses) on fixed asset investments | 44,291 | (33,956 ) |
| Net income/(expenditure) | 21,101 | (138,090 ) |
This page does not form part of the statutory financial
Page 18